DEA OKs Factory-Scale LSD and Pot Extract Bonanza

2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I

Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical often linked to illegal drug use—into Schedule I, the strictest drug category. This means anyone making, selling, or using it faces serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without adding new costs.

2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.

Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but the registration could speed up important drug studies.

2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance

The DEA is giving hexahydrocannabinol (HHC) its own official spot on the Schedule I drug list starting May 4, 2026. This means HHC, a synthetic cousin of THC, is clearly controlled as a hallucinogen with a unique code, making rules easier to follow. Anyone making, selling, or using HHC should know it’s officially regulated now, but no new fees or costs are added.

2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I

Starting May 1, 2026, the DEA officially puts four tricky chemicals—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these substances, who will face strict rules and possible penalties. The move helps keep dangerous synthetic drugs off the streets and protects public health.

2026-08176 — Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements

Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. Patients and companies benefit from easier access and clearer rules, while the government keeps control to meet international drug laws.

2026-08177 — Schedules of Controlled Substances: Rescheduling of Marijuana

The DEA is planning to move marijuana to Schedule III, which means it’s seen as less risky and easier to access legally. This change affects anyone using, selling, or researching marijuana and kicks off with a public hearing starting June 29, 2026. If you want to join the conversation, you need to sign up by May 28, 2026, so get ready for some big shifts in marijuana rules and opportunities!

Previous: 2026-06522 — Bulk Manufacturer of Controlled Substances Application: Research Triangle Institute

Research Triangle Institute wants to make large amounts of a controlled substance called tetrahydrocannabinols (THC) for research and testing. People who might be affected can share their thoughts or ask for a hearing by June 2, 2026. This move helps support scientific studies and doesn’t involve selling or other uses, just making the substance in bulk.

Next: 2026-06525 — Notice to All Interested Parties of Intent To Terminate Receivership

The FDIC is wrapping up its work with Citizens National Bank in Macomb, Illinois, and plans to officially end the receivership at least 30 days after this notice. Creditors can expect a final payment if funds allow. Anyone with thoughts about this decision has 30 days to send in their comments in writing.